Literature DB >> 8452516

Benzyloxycarbonyl-D-Phe-Pro-methoxypropylboroglycine: a novel inhibitor of thrombin with high selectivity containing a neutral side chain at the P1 position.

G Claeson1, M Philipp, E Agner, M F Scully, R Metternich, V V Kakkar, T DeSoyza, L H Niu.   

Abstract

Thrombin, the blood-clotting enzyme, is a serine proteinase with trypsin-like specificity and is able to cleave Arg-Xaa peptide bonds but only in a very limited number of substrates (and sites therein). For the prevention and treatment of thrombosis the control of thrombin activity is a key target, and a variety of synthetic inhibitors have been introduced recently, all of which have a positive charge at the P1 site. We report the synthesis of the first example of a new class of inhibitor containing a neutral side chain at the P1 site, the peptide benzyloxycarbonyl-D-Phe-Pro- methoxypropylboroglycine. The peptide is a potent inhibitor of thrombin [Ki (limiting) = 7 nM] and is highly selective for its target enzyme in respect of other serine proteinases. This may be expected to confer considerable advantage in terms of specificity of action and reduced toxicity over conventional, positively charged, inhibitors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8452516      PMCID: PMC1132273          DOI: 10.1042/bj2900309

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  16 in total

1.  Physical evidence for an apolar binding site near the catalytic center of human alpha-thrombin.

Authors:  L J Berliner; Y Y Shen
Journal:  Biochemistry       Date:  1977-10-18       Impact factor: 3.162

Review 2.  Regulation of thrombin generation and functions.

Authors:  J W Fenton
Journal:  Semin Thromb Hemost       Date:  1988-07       Impact factor: 4.180

3.  Anti-coagulant and anti-thrombotic effects of some protease inhibitors.

Authors:  C Mattson; E Eriksson; S Nilsson
Journal:  Folia Haematol Int Mag Klin Morphol Blutforsch       Date:  1982

4.  Inhibition of subtilisin by substituted arylboronic acids.

Authors:  M Philipp; S Maripuri
Journal:  FEBS Lett       Date:  1981-10-12       Impact factor: 4.124

5.  D-Phe-Pro-ArgCH2C1-A selective affinity label for thrombin.

Authors:  C Kettner; E Shaw
Journal:  Thromb Res       Date:  1979       Impact factor: 3.944

6.  H and 13C nuclear magnetic resonance spectra of some peptides with fibrinogen-like reactivity.

Authors:  I D Rae; H A Scheraga
Journal:  Int J Pept Protein Res       Date:  1979-03

7.  The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships.

Authors:  W Bode; D Turk; A Karshikov
Journal:  Protein Sci       Date:  1992-04       Impact factor: 6.725

8.  [The pharmacodynamics of synthetic thrombin inhibitors of the basic type substituted n-alpha arylsulfonylated phenylalanine amide].

Authors:  B Kaiser; J Hauptmann; F Markwardt
Journal:  Pharmazie       Date:  1987-02       Impact factor: 1.267

9.  High-resolution NMR studies of fibrinogen-like peptides in solution: interaction of thrombin with residues 1-23 of the A alpha chain of human fibrinogen.

Authors:  F Ni; Y Konishi; R B Frazier; H A Scheraga; S T Lord
Journal:  Biochemistry       Date:  1989-04-04       Impact factor: 3.162

10.  Serine protease mechanism: structure of an inhibitory complex of alpha-lytic protease and a tightly bound peptide boronic acid.

Authors:  R Bone; A B Shenvi; C A Kettner; D A Agard
Journal:  Biochemistry       Date:  1987-12-01       Impact factor: 3.162

View more
  1 in total

1.  Heparin enhances the catalytic activity of des-ETW-thrombin.

Authors:  C A Goodwin; J J Deadman; B F Le Bonniec; S Elgendy; V V Kakkar; M F Scully
Journal:  Biochem J       Date:  1996-04-01       Impact factor: 3.857

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.